Meeting report: Primary central nervous system lymphoma: Standards of care and future perspectives

Onkologie

Volumn 28, Issue 2, 2005, Pages 109-111

  Herrlinger, Ulrich ^a   Korfel, Agnieszka ^b   Hebart, Holger ^a   Schlegel, Uwe ^c   Plasswilm, Ludwig ^d   Illerhaus, Gerald ^e   Finke, Jürgen ^e   Krüger, William ^f   Montemurro, Michael ^f   Wolf, Timo ^g   Thiel, Eckhart ^b   Bamberg, Michael ^a   Weller, Michael ^a   Kanz, Lothar ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY OF FREIBURG   (Germany)

^f UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^g GOETHE UNIVERSITY   (Germany)

Author keywords

High dose chemotherapy; Methotrexate; Neurotoxicity; PCNSL

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; VINCRISTINE; VINDESINE;

CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG FATALITY; GERMANY; HUMAN; LEUKOENCEPHALOPATHY; LYMPHOMA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIMARY NERVOUS SYSTEM LYMPHOMA; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CLINICAL TRIALS; GERMANY; HUMANS; LYMPHOMA; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 20044384505     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083374     Document Type: Conference Paper

References (18)

1. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F: Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21:266-272.
2. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, Thomson JW, Murray KJ. Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the radiation therapy oncology group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23:9-17.
3. Hayabuchi N, Shibamoto Y, Onizuka Y: Primary central nervous system lymphoma in Japan: A nationwide survey. Int J Radiat Oncol Biol Phys 1999;44:265-272.
4. Shibamoto Y, Hayabuchi N, Hiratsuka J, Tokumaru S, Shirato H, Sougawa M, Oya N, Uematsu Y, Hiraoka M: Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer 2003;97:128-133.
5. Bessell EM, Lopez-Guillermo A, Villa S, Verger E, Nomdedeu B, Petit J, Byrne P, Montserrat E, Graus F: Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: An analysis of the CHOD/ BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002;20:231-236.
6. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter Q, Atasoy A, Klockgether T, Schlegel U: Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489-4495.
7. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaillard P, Reyes F, Lederlin P, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
8. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rube C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-633.
9. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
10. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, Bosly A, Morel P, Nouvel C, Tilly H, Lederlin P Sebban C, Briere J, Gaulard P, Reyes F: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol. 2000;18:3025-3030.
11. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL; Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287-1295.
12. Jacomet C, Girard PM, Lebrette MG, Farese VL, Monfort L, Rozenbaum W: Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS 1997;11:1725-1730.
13. Pels H, Schulz H, Manzke O, Hom E, Thall A, Engert A: Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 2002;59:213-216.
14. Fischer L, Thiel E, Klasen HA, Kirchen H, Jahnke K, Korfel A: Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 2004;62:1885-1887.
15. Wong ET, Tishler R, Barron L, Wu JK: Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004;101:139-145.
16. Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, Dell'Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJ: Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 2004;40:1682-1688.
17. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE: Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63:901-903.
18. Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M: Related Articles, Links Abstract One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004;62: 2113-2115.